Spots Global Cancer Trial Database for paraganglioma
Every month we try and update this database with for paraganglioma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease | NCT04891081 | Acyanotic Conge... Cyanotic Congen... Pheochromocytom... Paraganglioma | 18 Years - | University Medical Centre Ljubljana | ||
| Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma | NCT00911729 | Pheochromocytom... Paraganglioma | 18 Years - | Molecular Insight Pharmaceuticals, Inc. | ||
| The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma | NCT05702944 | Pheochromocytom... Paraganglioma Adrenalectomy; ... Adrenergics Cau... | Phenoxybenzamin... | 19 Years - 70 Years | Seoul National University Hospital | |
| A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma | NCT04187404 | Adrenocortical ... Pheochromocytom... Paraganglioma | EO2401 Nivolumab | 18 Years - | Enterome | |
| Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors | NCT05636618 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoid Tumor... Carcinoid Tumor Paraganglioma Pheochromocytom... | [212Pb]VMT-α-NE... [212Pb]VMT-α-NE... | 18 Years - 90 Years | Perspective Therapeutics | |
| Expanded Access Protocol Using 131I-MIBG | NCT01590680 | Neuroblastoma Pheochromocytom... Paraganglioma | I-131 MIBG | 12 Months - | Jubilant DraxImage Inc. | |
| "Receptor Radionuclide Therapy With 177Lu-DOTATOC | NCT06045260 | Neuroendocrine ... Paraganglioma Pheochromocytom... | 177Lu-DOTATOC | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Expanded Access Protocol Using 131I-MIBG | NCT01590680 | Neuroblastoma Pheochromocytom... Paraganglioma | I-131 MIBG | 12 Months - | Jubilant DraxImage Inc. | |
| Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma | NCT01941849 | Phaeochromocyto... Paraganglioma | Vandetanib 131I-mIBG | 18 Years - | University College, London | |
| Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma | NCT01941849 | Phaeochromocyto... Paraganglioma | Vandetanib 131I-mIBG | 18 Years - | University College, London | |
| Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma | NCT01838187 | Neuroblastoma Pheochromocytom... Paraganglioma | I-131 MIBG Vorinostat | 12 Months - | Children's Hospital Medical Center, Cincinnati | |
| A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma | NCT04187404 | Adrenocortical ... Pheochromocytom... Paraganglioma | EO2401 Nivolumab | 18 Years - | Enterome | |
| 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor | NCT05069220 | Neuroendocrine ... Neuroblastoma Pheochromocytom... Paraganglioma | 18F-MFBG 68Ga-Dotatate | 1 Year - 80 Years | Peking Union Medical College Hospital | |
| Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. | NCT04276597 | Pulmonary Neuro... Pheochromocytom... Paraganglioma Thymus Carcinoi... Unknown Primary... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... | 177Lu-DOTATOC | 18 Years - | Excel Diagnostics and Nuclear Oncology Center | |
| 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors | NCT01373736 | Pheochromocytom... Neuroblastoma Paraganglioma Medullary Thyro... Carcinoid Tumor... | 123I-meta-iodob... | - | Vancouver Coastal Health | |
| Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma | NCT00843037 | Paraganglioma Pheochromocytom... | Sunitinib | 18 Years - | University Health Network, Toronto | |
| Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease | NCT04891081 | Acyanotic Conge... Cyanotic Congen... Pheochromocytom... Paraganglioma | 18 Years - | University Medical Centre Ljubljana | ||
| Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents | NCT03923257 | Neuroendocrine ... Pheochromocytom... Paraganglioma | 177Lu-DOTA-tyr3... Peptide Recepto... | 1 Year - 20 Years | University of Iowa | |
| Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study | NCT04400474 | Neuroendocrine ... Anaplastic Thyr... Adenocarcinoma Pheochromocytom... Paraganglioma | Cabozantinib 40... | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| Head and Neck Paragangliomas: A 16-year Experience of a University Hospital in Turkey | NCT05942482 | Head and Neck P... | - | Pamukkale University | ||
| Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | NCT04119024 | Metastatic Mali... Metastatic Mela... Pathologic Stag... Pathologic Stag... Recurrent Malig... Refractory Mali... Uveal Melanoma Acral Melanoma Neuroendocrine ... Paraganglioma Pheochromocytom... Adrenocortical ... Pancreatic Neur... Thyroid Cancer Breast Cancer Lung Adenocarci... Head and Neck S... | Biopsy Biospecimen Col... Computed Tomogr... Cyclophosphamid... Fludarabine Pho... Fludeoxyglucose... IL13Ralpha2-spe... Magnetic Resona... Positron Emissi... | 18 Years - 70 Years | Jonsson Comprehensive Cancer Center | |
| Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card | NCT02672020 | Adrenal Gland N... | omics identity ... | 15 Years - | Assistance Publique - Hôpitaux de Paris | |
| A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL | NCT05885386 | Pheochromocytom... Paraganglioma | Temozolomide | 10 Years - 70 Years | Peking Union Medical College Hospital | |
| Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma | NCT01022515 | Pheochromocytom... Paraganglioma Essential Hyper... | plasma EM66 & C... usual follow up... | 18 Years - 90 Years | University Hospital, Rouen | |
| Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma | NCT02961491 | Pheochromocytom... Paraganglioma | Ultratrace Iobe... | 12 Years - | Molecular Insight Pharmaceuticals, Inc. | |
| Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma | NCT00911729 | Pheochromocytom... Paraganglioma | 18 Years - | Molecular Insight Pharmaceuticals, Inc. | ||
| Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial | NCT05142241 | Adrenal Gland P... Hematopoietic a... Malignant Solid... Paraganglioma | Biopsy Biospecimen Col... Computed Tomogr... Talazoparib Temozolomide | 12 Years - | National Cancer Institute (NCI) | |
| RAD001 and Erlotinib in Patients With Neuroendocrine Tumors | NCT00843531 | Neuroendocrine ... | RAD001 erlotinib | 18 Years - | University of California, San Francisco | |
| Fluorescence Guided Minimally-Invasive Resection Of Abdominal Paragangliomas Using Indocyanine Green | NCT06155734 | Paraganglioma | Fluorescence gu... | 18 Years - | Leiden University Medical Center | |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | NCT02834013 | Acinar Cell Car... Adenoid Cystic ... Adrenal Cortica... Adrenal Gland P... Anal Canal Neur... Anal Canal Undi... Angiosarcoma Apocrine Neopla... Appendix Mucino... Bartholin Gland... Basal Cell Carc... Bladder Adenoca... Breast Metaplas... Cervical Adenoc... Cholangiocarcin... Chordoma Colorectal Squa... Desmoid Fibroma... Endometrial Tra... Endometrioid Ad... Esophageal Neur... Esophageal Undi... Extrahepatic Bi... Extramammary Pa... Fallopian Tube ... Fallopian Tube ... Fibromyxoid Tum... Gallbladder Car... Gastric Neuroen... Gastric Squamou... Gastric Undiffe... Gastrointestina... Gestational Tro... Giant Cell Carc... Human Papilloma... Intestinal Neur... Intrahepatic Ch... Lung Neuroendoc... Lung Sarcomatoi... Major Salivary ... Malignant Odont... Malignant Perip... Malignant Solid... Malignant Testi... Metastatic Mali... Metastatic Pitu... Minimally Invas... Mixed Mesoderma... Mucinous Adenoc... Mucinous Cystad... Nasal Cavity Ad... Nasal Cavity Ca... Nasopharyngeal ... Nasopharyngeal ... Nasopharyngeal ... Oral Cavity Car... Oropharyngeal U... Ovarian Adenoca... Ovarian Germ Ce... Ovarian Mucinou... Ovarian Squamou... Ovarian Transit... Pancreatic Acin... Pancreatic Neur... Paraganglioma Paranasal Sinus... Paranasal Sinus... Parathyroid Gla... PEComa Penile Squamous... Peritoneal Meso... Placental Chori... Primary Periton... Pseudomyxoma Pe... Rare Disorder Scrotal Squamou... Seminal Vesicle... Seminoma Serous Cystaden... Small Intestina... Small Intestina... Spindle Cell Ne... Teratoma With S... Testicular Non-... Thyroid Gland C... Tracheal Carcin... Transitional Ce... Ureter Adenocar... Ureter Squamous... Urethral Adenoc... Urethral Squamo... Vaginal Adenoca... Vaginal Squamou... Vulvar Carcinom... | Biospecimen Col... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease | NCT04891081 | Acyanotic Conge... Cyanotic Congen... Pheochromocytom... Paraganglioma | 18 Years - | University Medical Centre Ljubljana | ||
| Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue (MICROBAT) | NCT04605848 | Pheochromocytom... Paraganglioma | Infrared themro... | 18 Years - 75 Years | University of Avignon | |
| ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid | NCT00339131 | Pheochromocytom... Paraganglioma Carcinoid | Ultratrace iobe... | 18 Years - | Molecular Insight Pharmaceuticals, Inc. | |
| Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors | NCT01560260 | Carney Complex Chondrosarcoma Gastrointestina... Paraganglioma | Laboratory Biom... Linsitinib Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma | NCT05636540 | Pheochromocytom... Paraganglioma | [18F]FluorThana... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies | NCT04895748 | Carcinoma, Rena... | DFF332 RAD001 PDR001 NIR178 | 12 Years - | Novartis | |
| 18F-FDOPA PET in Neuroendocrine Tumours | NCT02431715 | Thyroid Cancer,... Carcinoid Tumor Pheochromocytom... Paraganglioma Insulinoma Neuroblastoma | [18 F]-6-L-fluo... | 1 Month - | British Columbia Cancer Agency | |
| In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma | NCT05636540 | Pheochromocytom... Paraganglioma | [18F]FluorThana... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma | NCT00458952 | Pheochromocytom... Paraganglioma | Ultratrace Iobe... | 18 Years - | Molecular Insight Pharmaceuticals, Inc. | |
| Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma | NCT01967576 | Pheochromocytom... Paraganglioma | Axitinib (AG-01... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma | NCT01340794 | Extra-Adrenal P... Metastatic Adre... Paraganglioma Recurrent Adren... | Laboratory Biom... Pazopanib Hydro... | 18 Years - | National Cancer Institute (NCI) | |
| LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) | NCT03946527 | Paraganglioma Pheochromocytom... | Lanreotide | 18 Years - | Columbia University | |
| The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma | NCT05702944 | Pheochromocytom... Paraganglioma Adrenalectomy; ... Adrenergics Cau... | Phenoxybenzamin... | 19 Years - 70 Years | Seoul National University Hospital | |
| Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma | NCT03839498 | Pheochromocytom... Paraganglioma | Axitinib | 18 Years - | Columbia University | |
| Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma | NCT05082311 | Pheochromocytom... Paraganglioma Cardiovascular ... | Observational s... | 7 Years - | Sanjay Gandhi Postgraduate Institute of Medical Sciences | |
| GA-68 DOTA-TOC of Somatostatin Positive Malignancies | NCT02177773 | Neuroendocrine ... Paraganglioma Carcinoid Tumor... Neuroblastoma | Computed Tomogr... Gallium Ga 68-E... Magnetic Resona... Positron Emissi... | 2 Years - | University of California, San Francisco | |
| A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer | NCT03165721 | Paraganglioma Gastrointestina... Carcinoma, Rena... Renal Neoplasms Pheochromocytom... | SGI-110 (guadec... | 12 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Preoperative Alpha Blockade for Pheochromocytoma | NCT03176693 | Pheochromocytom... Paraganglioma | Phenoxybenzamin... Doxazosin | 18 Years - | University of California, Los Angeles | |
| The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma | NCT04860700 | Malignant Adren... Malignant Parag... Pheochromocytom... Paraganglioma, ... Paraganglioma, ... | anlotinib hydro... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors | NCT01413503 | Pheochromocytom... Paraganglioma | 131I-MIBG | 4 Years - | University of California, San Francisco | |
| Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions | NCT03160274 | Pheochromocytom... Paraganglioma Inherited Cance... Associated Cond... Kidney Neoplasm... Bone Cancer Thyroid Neoplas... Other Cancer | Genetic screeni... | - | The University of Texas Health Science Center at San Antonio | |
| 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors | NCT01373736 | Pheochromocytom... Neuroblastoma Paraganglioma Medullary Thyro... Carcinoid Tumor... | 123I-meta-iodob... | - | Vancouver Coastal Health | |
| In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma | NCT05636540 | Pheochromocytom... Paraganglioma | [18F]FluorThana... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL | NCT05883085 | Pheochromocytom... Paraganglioma | Anlotinib hydro... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents | NCT03923257 | Neuroendocrine ... Pheochromocytom... Paraganglioma | 177Lu-DOTA-tyr3... Peptide Recepto... | 1 Year - 20 Years | University of Iowa | |
| Expanded Access Protocol Using 131I-MIBG | NCT01590680 | Neuroblastoma Pheochromocytom... Paraganglioma | I-131 MIBG | 12 Months - | Jubilant DraxImage Inc. | |
| Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers | NCT00188019 | Paraganglioma Pheochromocytom... | diagnosis metho... | 6 Years - | University Hospital, Angers | |
| Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study | NCT04788927 | Paraganglioma Pheochromocytom... Genetic Predisp... Pathology Somatic Mutatio... Head and Neck C... Neuroendocrine ... | 0 Years - 120 Years | Rigshospitalet, Denmark | ||
| Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card | NCT02672020 | Adrenal Gland N... | omics identity ... | 15 Years - | Assistance Publique - Hôpitaux de Paris | |
| Prognostic's Factors of Head and Neck Paragangliomas Evolution | NCT05233878 | Paraganglioma | Characterizatio... | 18 Years - | Hospices Civils de Lyon | |
| Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. | NCT04276597 | Pulmonary Neuro... Pheochromocytom... Paraganglioma Thymus Carcinoi... Unknown Primary... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... | 177Lu-DOTATOC | 18 Years - | Excel Diagnostics and Nuclear Oncology Center | |
| A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors | NCT01413503 | Pheochromocytom... Paraganglioma | 131I-MIBG | 4 Years - | University of California, San Francisco | |
| A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL | NCT05885386 | Pheochromocytom... Paraganglioma | Temozolomide | 10 Years - 70 Years | Peking Union Medical College Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
